James Inglese

Last updated
James Inglese James Inglese.jpg
James Inglese

James Inglese is an American biochemist, the director of the Assay Development and Screening Technology Laboratory at the National Center for Advancing Translational Sciences, a Center within the National Institutes of Health. His specialty is small molecule high throughput screening. Inglese's laboratory develops methods and strategies in molecular pharmacology with drug discovery applications. The work of his research group and collaborators focuses on genetic and infectious disease-associated biology.

Contents

Biography

Inglese received his BS in Chemistry from the Rensselaer Polytechnic Institute in 1984 and a Ph.D. in Organic Chemistry from the Pennsylvania State University in 1989, where he conducted research under Stephen J. Benkovic on inhibitor design, synthesis and mechanism studies for the reduced folate-requiring enzymes. [1] He pursued postdoctoral studies on G protein-coupled receptors (GPCRs) with Robert J. Lefkowitz at the Duke University School of Medicine. During this time studied the emerging family of G protein-coupled receptor kinases (GRKs), discovering several lipid post-translational modifications regulating GRK function and GPCR interaction. [2]

Research

During the following 10 years, Inglese led research groups in the private sector. At the combinatorial chemistry biotech, Pharmacopeia Inc., he developed methods to enable the company's electrophoretic tag-encoded libraries, pioneering the development of technologies such as micro plate laser scanning cytometry for high throughput screening (HTS). [3] Subsequently, at the Merck Research Laboratories, he directed HTS assay development for the analysis of chemical libraries in the company's drug discovery efforts.

Inglese co-founded the NIH's Chemical Genomics Center (NCGC) in 2004. This came at a time when the academic community was divided with regard to the role of academics in drug development, with many thinking that this should be solely the domain of the pharmaceutical industry. [4] [5] He helped bring new technology and methods to drug development within the NIH. [6] As Deputy Director of the NCGC, he led the development of the Quantitative High Throughput Screening (qHTS) platform in 2006. [7] [8] [9] This pioneered a new approach to HTS that normally relies on a single concentration of a test compound [10] and has been cited over 500 times according to Scopus and Web of Science. Inglese has overseen the use of qHTS in numerous collaborative chemical probe discovery projects a. [11] According to Scopus, as of August 2020, Inglese has published 180 documents that have been cited over 12,400 times. Sixteen publications have been cited more than 200 times, while 35 have been cited 100 times or more. [12]

In 2009, his group's mechanistic studies of PTC124 (Ataluren), then in clinical trials for subclasses of cystic fibrosis and muscular dystrophy, revealed that the precursor discovery and subsequent development may have been guided by a confounding artifact of the reporter gene assay used in its identification and medicinal chemistry optimization. [13] [14] This led Inglese to design a new class of HTS reporter using the concept from physics of a coincidence circuit: [15] by joining two biochemically distinct reporters, separated by a P2A ribosome skipping site, one can distinguish between compounds that act at the level of reporter expression, which will affect both reporters, from compounds that directly affect the activity of one or the other reporter.

Complementing the laboratory's bioassay program, Inglese explores screening strategies to assess pharmacological activity, for example, from secondary metabolites contained in natural product extracts [16] or novel chemical scaffolds derived from synthetic chemistry methodology research. [17] His team's recent efforts have explored topologically expansive mRNA-encoded peptide libraries using a modified mRNA display to identify inhibitors of infectious disease molecular targets . [18] [19] This has led to the discovery of isozyme-selective phosphoglycerate mutase ligands, AKA Ipglycermides.

Professional activities

Inglese founded the journal ASSAY and Drug Development Technologies, serving as Editor-in-Chief from 2002 to 2014, and was Editor-in-Chief of the Methods in Enzymology volume 414 on Measuring Biological Responses with Automated Microscopy. [20]

Related Research Articles

<span class="mw-page-title-main">High-throughput screening</span> Drug discovery technique

High-throughput screening (HTS) is a method for scientific discovery especially used in drug discovery and relevant to the fields of biology, materials science and chemistry. Using robotics, data processing/control software, liquid handling devices, and sensitive detectors, high-throughput screening allows a researcher to quickly conduct millions of chemical, genetic, or pharmacological tests. Through this process one can quickly recognize active compounds, antibodies, or genes that modulate a particular biomolecular pathway. The results of these experiments provide starting points for drug design and for understanding the noninteraction or role of a particular location.

<span class="mw-page-title-main">Irwin Rose</span> American biologist

Irwin Allan Rose was an American biologist. Along with Aaron Ciechanover and Avram Hershko, he was awarded the 2004 Nobel Prize in Chemistry for the discovery of ubiquitin-mediated protein degradation.

A chemical compound microarray is a collection of organic chemical compounds spotted on a solid surface, such as glass and plastic. This microarray format is very similar to DNA microarray, protein microarray and antibody microarray. In chemical genetics research, they are routinely used for searching proteins that bind with specific chemical compounds, and in general drug discovery research, they provide a multiplex way to search potential drugs for therapeutic targets.

Hit to lead (H2L) also known as lead generation is a stage in early drug discovery where small molecule hits from a high throughput screen (HTS) are evaluated and undergo limited optimization to identify promising lead compounds. These lead compounds undergo more extensive optimization in a subsequent step of drug discovery called lead optimization (LO). The drug discovery process generally follows the following path that includes a hit to lead stage:

<span class="mw-page-title-main">Meir Wilchek</span> Israeli biochemist (born 1935)

Meir Wilchek is an Israeli biochemist. He is a professor at the Weizmann Institute of Science.

<span class="mw-page-title-main">Ataluren</span> Duchenne muscular dystrophy medication

Ataluren, sold under the brand name Translarna, is a medication for the treatment of Duchenne muscular dystrophy. It was designed by PTC Therapeutics.

<span class="mw-page-title-main">GRK6</span> Protein-coding gene in the species Homo sapiens

This gene encodes a member of the G protein-coupled receptor kinase subfamily of the Ser/Thr protein kinase family, and is most highly similar to GRK4 and GRK5. The protein phosphorylates the activated forms of G protein-coupled receptors to regulate their signaling.

<span class="mw-page-title-main">DIDO1</span> Protein-coding gene in the species Homo sapiens

Death-inducer obliterator 1 is a protein that in humans is encoded by the DIDO1 gene.

<span class="mw-page-title-main">MYH14</span> Protein-coding gene in the species Homo sapiens

Myosin-14 is a protein that in humans is encoded by the MYH14 gene.

<span class="mw-page-title-main">ZNF638</span> Protein-coding gene in the species Homo sapiens

Zinc finger protein 638 is a protein that in humans is encoded by the ZNF638 gene.

<span class="mw-page-title-main">RBM15</span> Protein-coding gene in the species Homo sapiens

Putative RNA-binding protein 15 is a protein that in humans is encoded by the RBM15 gene. It is an RNA-binding protein that acts as a key regulator of N6-Methyladenosine (m6A) methylation of RNAs

<span class="mw-page-title-main">MORC2</span> Protein-coding gene in the species Homo sapiens

MORC family CW-type zinc finger protein 2 is a protein that in humans is encoded by the MORC2 gene.

<span class="mw-page-title-main">DYNC1LI2</span> Protein-coding gene in the species Homo sapiens

Cytoplasmic dynein 1 light intermediate chain 2 is a protein that in humans is encoded by the DYNC1LI2 gene.

<span class="mw-page-title-main">WDR46</span> Protein-coding gene in the species Homo sapiens

WD repeat-containing protein 46 is a protein that in humans is encoded by the WDR46 gene.

<span class="mw-page-title-main">CTR9</span> Protein-coding gene in the species Homo sapiens

RNA polymerase-associated protein CTR9 homolog is an enzyme that in humans is encoded by the CTR9 gene.

<span class="mw-page-title-main">PSRC1</span> Protein-coding gene in the species Homo sapiens

Proline/serine-rich coiled-coil protein 1 is a protein that in humans is encoded by the PSRC1 gene.

<span class="mw-page-title-main">ACER2</span> Ceramidase enzyme

Alkaline ceramidase 2 also known as ACER2 is a ceramidase enzyme which in humans is encoded by the ACER2 gene.

<span class="mw-page-title-main">Jonathan Stamler</span> English-American physician and biochemist

Jonathan Solomon Stamler is an English-born American physician and scientist. He is known for his discovery of protein S-nitrosylation, the addition of a nitric oxide (NO) group to cysteine residues in proteins, as a ubiquitous cellular signal to regulate enzymatic activity and other key protein functions in bacteria, plants and animals, and particularly in transporting NO on cysteines in hemoglobin as the third gas in the respiratory cycle.

Milan Mrksich is an American chemist. He is the Henry Wade Rogers Professor at Northwestern University with appointments in chemistry, biomedical engineering and cell & developmental biology. He also served as both the founding director of the Center for Synthetic Biology and as an associate director of the Robert H. Lurie Comprehensive Cancer Center at Northwestern. Mrksich also served as the Vice President for Research of Northwestern University.

John Mekalanos is a microbiologist who is primarily known for leading one of the first teams that reported the discovery of the type VI secretion system as well as his work on the pathogenicity of the bacterial species Vibrio cholerae, its toxin, and its secretion systems. Since 1998, he has been a member of the National Academy of Sciences.

References

  1. ↑ Inglese, J.; Blatchly, R.A.; Benkovic, S.J. (1989). "A Multisubstrate Adduct Inhibitor of a Purine Biosynthetic Enzyme with a Picomolar Dissociation Constant". J. Med. Chem. 32 (5): 937–940. doi:10.1021/jm00125a002. PMID   2709379.
  2. ↑ Inglese, J.; Glickman, J.F.; Lorenz, W.; Caron, M.G.; Lefkowitz, R.J. (1992). "Isoprenylation of a Protein Kinase: Farnesylation / α-Carboxyl Methylation Required for Full Enzymatic Activity of Rhodopsin Kinase". J. Biol. Chem. 267 (3): 1422–1425. doi: 10.1016/S0021-9258(18)45960-1 . PMID   1730692.
  3. ↑ Zuck, P.; Lao, Z.; Skwish, S.; Glickman, J.F.; Yang, K.; Burbaum, J.; Inglese, J. (1999). "Ligand-receptor binding measured by laser-scanning imaging". Proc. Natl. Acad. Sci. U.S.A. 96 (20): 11122–11127. Bibcode:1999PNAS...9611122Z. doi: 10.1073/pnas.96.20.11122 . PMC   17997 . PMID   10500140.
  4. ↑ "NIH INITIATIVES TARGET CHEMISTRY | January 3, 2005 Issue - Vol. 83 Issue 1 | Chemical & Engineering News". cen.acs.org. Archived from the original on 2020-06-12.
  5. ↑ Alexander DF, Alving BM, Battey JF, et al. (2006). "Response to: "Rescuing the NIH before it is too late"". J Clin Invest. 116 (6): 1462–2. doi: 10.1172/JCI28894 . PMC   1449952 . PMID   16648877.
  6. ↑ "Drug discovery and development: A complex team sport". Science | AAAS. March 7, 2008.
  7. ↑ "High-Throughput Screening at Multiple Concentrations".
  8. ↑ "Screening made easier".
  9. ↑ Inglese, J.; Auld, D.S.; Jadhav, A.; Johnson, R.L.; Simeonov, A.; Yasgar, A.; Zheng, W.; Austin, C.P. (2006). "Quantitative High-Throughput Screening (qHTS): A Titration-based Approach that Efficiently Identifies Biological Activities in Large Chemical Libraries". Proc. Natl. Acad. Sci. USA. 103 (31): 11473–11478. doi: 10.1073/pnas.0604348103 . PMC   1518803 . PMID   16864780.
  10. ↑ Shockley, K.R.; Gupta, S.; Harris, S.F.; Lahiri, S.N.; Peddada, S.D. (2019). "Quality Control of Quantitative High Throughput Screening Data". Front. Genet. 10: 387. doi: 10.3389/fgene.2019.00387 . PMC   6520559 . PMID   31143201.
  11. ↑ "Slaying Cancer At Its Roots | February 15, 2010 Issue - Vol. 88 Issue 7 | Chemical & Engineering News". cen.acs.org. Archived from the original on 2020-04-07.
  12. ↑ "Scopus preview - Inglese, J. - Author details - Scopus". www.scopus.com.
  13. ↑ Sheridan, C. (2013). "Doubts raised over 'read-through' Duchenne drug mechanism". Nature Biotechnology. 31 (9): 771–773. doi:10.1038/nbt0913-771. PMID   24022133. S2CID   36275525.
  14. ↑ Auld, D.S.; Lovell, S.; Thorne, N.; Lea, W.A.; Maloney, D.J.; v; Rai, G.; Battaile, K.P.; Thomas, C.J.; Simeonov, A.; Hanzlik, R.P.; Inglese, J. (2010). "Molecular basis for the high-affinity binding and stabilization of firefly luciferase by PTC124". Proc. Natl. Acad. Sci. USA. 107 (11): 4878–4883. Bibcode:2010PNAS..107.4878A. doi: 10.1073/pnas.0909141107 . PMC   2841876 . PMID   20194791.
  15. ↑ Cheng, K.C.; Inglese, J. (2012). "A coincidence reporter-gene system for high throughput screening". Nature Methods. 9 (10): 937. doi: 10.1038/nmeth.2170 . PMC   4970863 . PMID   23018994.
  16. ↑ Cheng, K.C.; Cao, S.; Raveh, A.; MacArthur, R.; Dranchak, P.; Chlipala, G.; Okoneski, M.T.; Guha, R.; Eastman, R.T.; Yuan, J.; Schultz, P.J.; Su, X.,Z.; Tamayo-Castillo, G.; Matainaho, T.; Clardy, J.; Sherman, D.H.; Inglese, J. (2015). "Actinoramide A identified as a potent antimalarial from titration-based screening of marine natural product extracts". Natural Products. 78 (10): 2411–2422. doi:10.1021/acs.jnatprod.5b00489. PMC   4633019 . PMID   26465675.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  17. ↑ Brown, L.E.; Cheng, K.C.; Wei, W.G.; Yuan, P.; Dai, P.; Trilles, R.; Ni, F.; Yuan, J.; MacArthur, R.; Guha, R.; Johnson, R.L.; Su, X.,Z.; Dominguez, M.M.; Snyder, J.K.; Beeler, A.B.; Schaus, S.E.; Inglese, J.; Porco, J.A. Jr. (2011). "Discovery of New Anti-Malarial Chemotypes through Chemical Methodology and Library Development". Proc. Natl. Acad. Sci. USA. 108 (17): 6775–6780. doi: 10.1073/pnas.1017666108 . PMC   3084078 . PMID   21498685.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  18. ↑ Says, Zain Malik (April 11, 2017). "Fighting Parasitic Infections: Promise in Cyclic Peptides". NIH Director's Blog.
  19. ↑ "International scientific teams find potential approach against parasites". National Institutes of Health (NIH). March 28, 2017.
  20. ↑ "Measuring Biological Responses with Automated Microscopy, Volume 414 - 1st Edition". www.elsevier.com.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.